Core Viewpoint - Aktis Oncology, Inc. has successfully closed its upsized initial public offering (IPO) of 17,650,000 shares at a price of $18.00 per share, with additional shares bringing total gross proceeds to approximately $365.4 million [1]. Company Overview - Aktis Oncology is a clinical-stage oncology company focused on targeted radiopharmaceuticals aimed at large patient populations, including those not served by existing technologies [4]. - The company's advanced pipeline program targets Nectin-4, utilizing a miniprotein radioconjugate platform designed to deliver radioisotopes selectively to tumors while minimizing side effects [4]. - Aktis' platform is isotope-agnostic, allowing for visualization and verification of target engagement with imaging isotopes before therapeutic exposure [4]. - The company has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates beyond its proprietary pipeline [4]. IPO Details - The IPO was completed on January 12, 2026, with the underwriters fully exercising their option to purchase an additional 2,647,500 shares, expected to close on January 14, 2026 [1]. - The total gross proceeds from the IPO, including the additional shares, are anticipated to be around $365.4 million before deducting underwriting discounts and commissions [1]. - Aktis' common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026 [1].

Company Overview - Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals for large patient populations, including those not addressed by existing technologies [5] - The company's most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with potential applications across multiple tumor types [5] - Aktis has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver tumor-killing properties of radioisotopes to targeted tumors while minimizing side effects [5] - The platform is isotope-agnostic and allows clinicians to visualize and verify target engagement with imaging isotopes before therapeutic exposure [5] - Aktis has a strategic collaboration with Eli Lilly and Company to develop novel radioconjugates outside of its proprietary pipeline [5] IPO Details - Aktis announced the pricing of its upsized initial public offering of 17,650,000 shares at a price of $18.00 per share, with gross proceeds expected to be approximately $318.0 million [1] - The underwriters have a 30-day option to purchase up to an additional 2,647,500 shares at the initial public offering price [1] - The common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026, with the offering expected to close on January 12, 2026 [1]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Aktis Oncology has become the first biotechnology company to file for an initial public offering in several weeks, outlining on Friday a stock issuance to help advance a pipeline of radiopharmaceuticals for cancer. Aktis specializes in what it calls “miniprotein radioconjugates,” which it believes to be capable of accessing tumor targets that are ...